CoChat
Sign Up
Cited by 5Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsColorectal Cancer Surgical Treatments

436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

Open access
Ahn, D.H., Erlander, M., Ridinger, M., Samuëlsz, E., Barzi, A., Bekaii-Saab, T., Lenz, H.J.·2020·Annals of Oncology
DOI 10.1016/j.annonc.2020.08.547
Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.08.547

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The PLK1 inhibitor onvansertib combined with chemotherapy and bevacizumab in KRAS mutant metastatic colorectal cancer in a phase II trial seems to demonstrate favorable tolerability and clinical response.

    “Recently, the PLK1 inhibitor onvansertib has been evaluated in combination with chemotherapy and bevacizumab in KRAS mutant metastatic colorectal cancer in a phase II trial, and this combination seems to demonstrate favorable tolerability and clinical response (36).”

    From KRAS mutation in pancreatic cancer (2021) · cites this paper as [36]

Cited by

Sorted by citations

Related

Authors
Ahn, D. H., Erlander, M., Ridinger, M., Samuëlsz, E., Barzi, A., Bekaii-Saab, T., & Lenz, H. J.
Affiliations
  • Mayo Clinic Hospital (US)
  • City Of Hope National Medical Center (US)
  • University of Southern California (US)
ORCID
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-09
Volume
31
Pages
S427
ISSN
0923-7534 (ISSN-L)
DOI
10.1016/j.annonc.2020.08.547
OpenAlex
W3088054599
Cited by
5
References
0
Citations by year
2025: 1 · 2023: 1 · 2021: 3
FWCI
0.36
Type
journal article
Language
en
Open access
Licence
Locations
Annals of Oncology (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
onvansertib, polo-like kinase 1 inhibitor, FOLFIRI, bevacizumab, second-line therapy, synthetic lethality, dose escalation, maximum tolerated dose, neutropenia, liquid biopsy, progression-free survival, irinotecan, 5-fluorouracil

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review